+

WO2007001928A3 - Cibles pour l'inhibition de la replication du virus de l'hepatite c - Google Patents

Cibles pour l'inhibition de la replication du virus de l'hepatite c Download PDF

Info

Publication number
WO2007001928A3
WO2007001928A3 PCT/US2006/023646 US2006023646W WO2007001928A3 WO 2007001928 A3 WO2007001928 A3 WO 2007001928A3 US 2006023646 W US2006023646 W US 2006023646W WO 2007001928 A3 WO2007001928 A3 WO 2007001928A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
replication
identified
hcv replication
hcv
Prior art date
Application number
PCT/US2006/023646
Other languages
English (en)
Other versions
WO2007001928A2 (fr
Inventor
Amy S. Espeseth
Daria Hazuda
Adam T. Gates
Giovanni Migliaccio
Raffaele De Francesco
Peter Linsley
Original Assignee
Merck & Co., Inc.
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.
Rosetta Inpharmatics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A., Rosetta Inpharmatics Llc filed Critical Merck & Co., Inc.
Priority to CA002611528A priority Critical patent/CA2611528A1/fr
Priority to JP2008518260A priority patent/JP2009501513A/ja
Priority to AU2006262490A priority patent/AU2006262490A1/en
Priority to EP06785052A priority patent/EP1896619A2/fr
Publication of WO2007001928A2 publication Critical patent/WO2007001928A2/fr
Publication of WO2007001928A3 publication Critical patent/WO2007001928A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention a trait à des protéines exprimées par le foie impliquées dans la réplication du virus de l'hépatite C qui ont été identifiées au moyen d'une procédure consistant à mesurer l'effet d'expression inhibitrice de protéines de cellule hôte sur l'activité de réplicon du virus de l'hépatite C. Les protéines identifiées et l'acide nucléique codant fournissent des cibles pour l'inhibition de la réplication du virus de l'hépatite C. Des composés d'inhibition du virus de l'hépatite C comprennent des composés ciblant des protéines identifiées et des composés ciblant l'acide nucléique codant pour la protéine identifiée. On a également constaté que plusieurs parmi les gènes hôtes identifiés comme cibles pour l'inhibition de la réplication du virus de l'hépatite C sont une cible pour l'inhibition de la réplication du virus de l'hépatite C. La capacité d'agir comme cible pour l'inhibition à la fois de la réplication de VIH et de VHC indique qu'un tel gène identifié et la protéine codée peuvent être une cible utile pour l'inhibition de la réplication de différents types de virus et non limités à l'inhibition de la réplication d'un virus particulier.
PCT/US2006/023646 2005-06-22 2006-06-16 Cibles pour l'inhibition de la replication du virus de l'hepatite c WO2007001928A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002611528A CA2611528A1 (fr) 2005-06-22 2006-06-16 Cibles pour l'inhibition de la replication du virus de l'hepatite c
JP2008518260A JP2009501513A (ja) 2005-06-22 2006-06-16 Ｈｃｖ複製阻害の標的
AU2006262490A AU2006262490A1 (en) 2005-06-22 2006-06-16 Targets for inhibiting HCV replication
EP06785052A EP1896619A2 (fr) 2005-06-22 2006-06-16 Cibles pour l'inhibition de la réplication du virus de l'hépatite c

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69282105P 2005-06-22 2005-06-22
US60/692,821 2005-06-22
US71000605P 2005-08-19 2005-08-19
US60/710,006 2005-08-19

Publications (2)

Publication Number Publication Date
WO2007001928A2 WO2007001928A2 (fr) 2007-01-04
WO2007001928A3 true WO2007001928A3 (fr) 2011-05-26

Family

ID=37595694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023646 WO2007001928A2 (fr) 2005-06-22 2006-06-16 Cibles pour l'inhibition de la replication du virus de l'hepatite c

Country Status (5)

Country Link
EP (1) EP1896619A2 (fr)
JP (1) JP2009501513A (fr)
AU (1) AU2006262490A1 (fr)
CA (1) CA2611528A1 (fr)
WO (1) WO2007001928A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722263B1 (ko) * 2007-07-05 2017-03-31 애로우헤드 리서치 코오포레이션 바이러스 감염을 치료하기 위한 ｄｓＲＮＡ
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
US20100183704A1 (en) * 2008-09-25 2010-07-22 Novartis Ag dsRNA FOR TREATING VIRAL INFECTION
WO2010137570A1 (fr) * 2009-05-29 2010-12-02 学校法人慶應義塾 Agent antiviral ou agent anticancéreux
WO2021143931A1 (fr) * 2020-01-19 2021-07-22 北京生命科学研究所 Facteur hôte spécifique de l'infection par le virus de l'hépatite b et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"PI4KA-HUMAN. Uniprotein", 10 May 2005 (2005-05-10), Retrieved from the Internet <URL:httpJ/www.uniprot.org/uniproUP42356.bctTversion=40> [retrieved on 20090720] *
AZA-BLANC ET AL.: "Identification of modulators of TRAIL-Induced Apoptosis via RNAI-based Phenotypic Screening", MOL. CELL., vol. 12, no. 3, September 2003 (2003-09-01), pages 627 - 637 *
KIM ET AL.: "Protein kinase C-related kinase 2 regulates hepatitis C virus RNA polymerase function by phosphorylation.", J. BIOL. CHEM., vol. 279, no. 48, 26 November 2004 (2004-11-26), pages 50031 - 50041 *
MAZZOCCA ET AL.: "Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.", J. BIOL. CHEM., vol. 280, no. 12, 25 March 2005 (2005-03-25), pages 11329 - 11339 *
SCHMID-ANTOMARCH.: "HIV Induces activation of phosphatidyllnositol4-klnase and mitogen- activated protein kinase by interacting with T cell CD4 surface molecules.", EUR. J. IMMUNOL., vol. 26, 1996, pages 717 - 720 *

Also Published As

Publication number Publication date
WO2007001928A2 (fr) 2007-01-04
AU2006262490A1 (en) 2007-01-04
JP2009501513A (ja) 2009-01-22
CA2611528A1 (fr) 2007-01-04
EP1896619A2 (fr) 2008-03-12

Similar Documents

Publication Publication Date Title
Eiermann et al. Dance with the devil: stress granules and signaling in antiviral responses
Panas et al. Sequestration of G3BP coupled with efficient translation inhibits stress granules in Semliki Forest virus infection
EP4397759A3 (fr) Composition pour le clivage d&#39;un adn cible comprenant un arn guide spécifique de l&#39;adn cible et un acide nucléique codant pour la protéine cas ou la protéine cas, et leur utilisation
Sohn et al. Adenoviral strategies to overcome innate cellular responses to infection
WO2007002008A3 (fr) Procedes et compositions permettant d&#39;exprimer un virus a arn sens negatif dans des cellules canines
WO2010057203A3 (fr) Particules de hdl pour administration d&#39;acides nucléiques
JP2018082709A5 (fr)
WO2008140621A3 (fr) Virus oncolytiques transgéniques et leurs utilisations
WO2007124327A3 (fr) Méthodes et compositions d&#39;expression d&#39;arn viral sens négatif dans des cellules canines
WO2008051928A3 (fr) Amplification ciblée d&#39;un génome entier d&#39;acides nucléiques
WO2007014275A3 (fr) Integration et expression ciblees de sequences d&#39;acides nucleiques exogenes
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
EP3418386A3 (fr) Compositions et méthodes permettant d&#39;inhiber l&#39;expression d&#39;un gène du virus de l&#39;hépatite b
WO2008033413A3 (fr) Protéines de fusion d&#39;albumine
WO2009131919A8 (fr) Polymérases pour incorporer des nucléotides modifiés
WO2002008286A3 (fr) Code de reconnaissance pour domaines en doigt de zinc et ses utilisations
WO2010107739A3 (fr) Méthodes et compositions pour traiter l&#39;infection par un virus de la famille des flaviviridae
WO2007001928A3 (fr) Cibles pour l&#39;inhibition de la replication du virus de l&#39;hepatite c
EP2527445A3 (fr) Traitement et prévention de la grippe
WO2008129971A1 (fr) Vecteur amélioré du virus sendai infectant de manière persistante
WO2010042755A3 (fr) Agents thérapeutiques chimères, compositions et méthodes d&#39;utilisation
WO2007094818A3 (fr) Nouvelles cibles vih
WO2007089732A3 (fr) Amélioration des niveaux et/ou de la durabilité de l&#39;expression génique à base d&#39;adn
WO2005118813A3 (fr) Acides nucleiques, polypeptides, methodes d&#39;expression, et compositions immunogenes associees a la proteine spike du coronavirus sras
WO2009131683A3 (fr) Méthode de détection du virus du chikungunya

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006785052

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2611528

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006262490

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008518260

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006262490

Country of ref document: AU

Date of ref document: 20060616

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载